National Development and Reform Commission: analysis of the economic operation of the pharmaceutical industry in 2017

Source: National Development and Reform Commission 2018-03-27 in 2017, the development trend of the pharmaceutical industry is generally good, the main business income, total foreign trade and total profits maintain a rapid growth, and the main business income is restored to double-digit growth, playing an important role in ensuring supply, stabilizing growth and adjusting structure 1、 The growth of main business has been accelerated, and the industrial scale has been growing steadily In 2017, the main business income of Pharmaceutical Enterprises above Designated Size reached 2982.6 billion yuan, an increase of 12.2% year on year, 2.3 percentage points higher than that in 2016, returning to double-digit growth The growth of the main business income of the 8 sub industries is shown in the table below, among which the fastest growth is in the processing industry of Chinese herbal pieces and the manufacturing industry of chemical raw materials In 2017, the main business income of the molecular industry of the pharmaceutical industry (RMB 100 million) the proportion (%) year on year (%) of the main business income of the industry (RMB 100 million) the manufacturing of chemical raw materials drugs 4991.7 14.7 16.7 the manufacturing of chemical preparations 8340.6 12.9 28.0 the processing of Chinese herbal pieces 2165.3 16.7 7.3 the production of Chinese patent medicine 5735.8.4 19.2 Manufacturing of biological drugs 3311.0 11.8 11.1 manufacturing of health materials and medical supplies 2266.8 13.5 7.6 manufacturing of special equipment for pharmaceutical 186.7 7.7 0.6 manufacturing of medical instruments and devices 2828.11 10.7 9.5 total 29826.0 12.2100 II Investment in fixed assets decreased, and enterprise benefits increased steadily In 2017, the completed investment was 598.63 billion yuan, down 3.0% year-on-year, 7.8 percentage points lower than the growth rate of industrial fixed asset investment in the same period In recent years, the new GMP certification is coming to an end, and the improvement of product quality, such as consistency evaluation, has been accelerated Some enterprises choose to abandon some varieties, projects or postpone the construction of projects in the evaluation, which has a certain impact on the investment in fixed assets At the same time, with the deepening of the restructuring of the pharmaceutical industry, in 2017, the total profits of Enterprises above Designated Size reached 351.97 billion yuan, an increase of 16.6% year-on-year, and an increase of 1.0 percentage points The growth rate of profit is higher than that of main business income, and the overall profit level of the industry has been improved The profit growth of the eight sub industries is shown in the table below The fastest growth is in the bio pharmaceutical manufacturing industry and the chemical pharmaceutical manufacturing industry The industrial development momentum is constantly shifting to high value-added products In 2017, the total profit of the molecular industry of the pharmaceutical industry (100 million yuan) the proportion of the total profit of the industry (%) compared with the same period of last year (%) (436.113.7, 12.4, 1170.3, 22.1, 33.2, 153.4, 15.1, 4.4, 707.2, 10.0, 20.1, biopharmaceutical manufacturing) 499.0 26.8 14.2 manufacturing of health materials and medical supplies According to the import and export data of the customs, in 2017, China's total import and export trade of pharmaceutical products reached US $116.68 billion, a year-on-year increase of 12.6%; the import value was US $55.88 billion, a year-on-year increase of 16.3%; the export value was US $60.80 billion, a year-on-year increase of 9.4%, a growth rate of nearly five years The trade surplus was US $4.92 billion, down 34.6% year on year Both import and export have shown rapid growth On the one hand, the growing health demand of the people has driven the import of pharmaceutical products At the same time, the continuous promotion of supply side reform and the acceleration of internationalization process by local enterprises have also brought about rapid growth in export, reversing the decline in export volume in 2016 Statistics of import and export structure of pharmaceutical products in 2017 commodity name export amount (US $100 million) export amount year-on-year growth (%) import amount (US $100 million) import amount year-on-year growth (%) total 608.09.4558.8 16.3 traditional Chinese medicine 36.42.1 15.6 26.1 extract 20.14.3 6.1 16.0 proprietary Chinese medicine 2.5 11.0 3.7 14.4 traditional Chinese medicine and pieces 11.4-2.2 2.6 26.7 health products 2.4-3.4 3.2 69.5 western medicine 354.6 12.6 339.6 19.6 western medicine 291.2 13.7 87.2 14.3 Western patent medicine 34.6 8.3 171.6 21.66 biochemical medicine 28.8 7.4 80.8 21.5 medical devices 217.0 5.8 203.6 10.6 medical dressing 24.3 3.0 3.7 9.2 disposable consumables 36.1 9.5 29.3 11.3 hospital diagnosis and treatment 94.0 4.1 146.3 9.6 health rehabilitation supplies 54.3 6.3 16.5 12.1 oral equipment and materials 8.3 17.0 7.8 26.8 4、 The pharmaceutical innovation is vigorous and the achievements of innovation industrialization are outstanding The investment in pharmaceutical innovation has continued to grow On the one hand, policies such as "major new drug creation" major science and technology projects, and three-year action plan to enhance core competitiveness continue to increase support for pharmaceutical innovation and R & D and industrialization of innovation achievements On the other hand, a number of industry leading enterprises with large R & D investment and significant innovation achievements have emerged According to the annual report of listed companies, Hengrui, Fosun, Haizheng, etc The R & D investment in the industry has reached about 10% of the sales revenue, a large number of capital has poured into the field of pharmaceutical innovation, and a number of innovative growth enterprises have successfully financed, effectively promoting the research of high-risk, long-term innovative drugs At the same time, with the deepening of the review and approval reform, a series of measures, such as accelerating the review and approval of innovative drugs and medical devices, pilot drug listing license holder system, optimizing the review and approval process, have been rapidly promoted, greatly improving the review and approval efficiency, and the pharmaceutical innovation environment has been significantly improved In 2017, the "recombinant Ebola virus vaccine" independently researched and developed by China and with full independent intellectual property rights was approved as the first one in the world A number of innovative medical device products, such as bortezomib, tenofovir fumarate dipivoxil, parecoxib sodium, caspofungin, lenalidomide, and trypatide, were approved for market, and a batch of innovative medical device products, such as interventional artificial heart valve, were continuously filled Domestic gaps in various fields play an important role in improving people's access to medication and reducing the burden of disease.